| Chad Edward Hartley, MD | |
|
72 Lake Havasu Ave S Ste 102, Lake Havasu City, AZ 86403-0857 | |
| (928) 453-2211 | |
| (928) 453-2213 |
| Full Name | Chad Edward Hartley |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 23 Years |
| Location | 72 Lake Havasu Ave S Ste 102, Lake Havasu City, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457513749 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 46605 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Havasu Regional Medical Center | Lake havasu city, AZ | Hospital |
| Kingman Regional Medical Center | Kingman, AZ | Hospital |
| Valley View Medical Center | Fort mohave, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Panacea Brain And Spine Llc | 0648423525 | 2 |
| Paragon Physical Therapy And Rehab Llc | 4284902339 | 55 |
News Archive
Biodel Inc. today reported financial results for the fourth quarter and fiscal year ended September 30, 2009.
Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Bariatric surgeons at Central Baptist Hospital made U.S. medical history Feb. 16 by performing a groundbreaking bariatric procedure to decrease the capacity of a patient's stomach without making a single incision into her body.
Vaccinations are the safest way to protect against disease. However, many vaccines become ineffective when exposed to room temperature or heat.
› Verified 2 days ago
| Entity Name | Panacea Brain And Spine Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457622763 PECOS PAC ID: 0648423525 Enrollment ID: O20121228000141 |
News Archive
Biodel Inc. today reported financial results for the fourth quarter and fiscal year ended September 30, 2009.
Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Bariatric surgeons at Central Baptist Hospital made U.S. medical history Feb. 16 by performing a groundbreaking bariatric procedure to decrease the capacity of a patient's stomach without making a single incision into her body.
Vaccinations are the safest way to protect against disease. However, many vaccines become ineffective when exposed to room temperature or heat.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Chad Edward Hartley, MD 72 Lake Havasu Ave S Ste 102, Lake Havasu City, AZ 86403-0857 Ph: (928) 453-2211 | Chad Edward Hartley, MD 72 Lake Havasu Ave S Ste 102, Lake Havasu City, AZ 86403-0857 Ph: (928) 453-2211 |
News Archive
Biodel Inc. today reported financial results for the fourth quarter and fiscal year ended September 30, 2009.
Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.
Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.
Bariatric surgeons at Central Baptist Hospital made U.S. medical history Feb. 16 by performing a groundbreaking bariatric procedure to decrease the capacity of a patient's stomach without making a single incision into her body.
Vaccinations are the safest way to protect against disease. However, many vaccines become ineffective when exposed to room temperature or heat.
› Verified 2 days ago